Literature DB >> 9790813

TNF binding protein prevents hyperlactatemia and inactivation of PDH complex in skeletal muscle during sepsis.

T C Vary1, S A Hazen, G Maish, R N Cooney.   

Abstract

BACKGROUND: Hyperlactatemia is a metabolic complication of hypermetabolic, hyperdynamic sepsis. An important mechanism responsible for elevating plasma lactate concentrations in sepsis is altered regulation of the pyruvate dehydrogenase complex (PDH) in skeletal muscle. We investigated the ability of a specific tumor necrosis factor binding protein, TNFbp, to modulate lactate concentrations and skeletal muscle PDH activity in a rodent model of chronic abdominal sepsis.
MATERIALS AND METHODS: We examined the regulation of lactate metabolism in four groups of animals: Control, Control + TNFbp, Septic, and Septic + TNFbp. Chronic (5 days) sepsis was induced by the creation of a stable intraabdominal abscess using a sterile fecal-agar pellet inoculated with E. coli plus B. Fragilis as the foreign body nidus. TNFbp (1 mg/kg/day) was injected subcutaneously daily.
RESULTS: Sepsis increased plasma and skeletal muscle lactate concentrations 2-fold compared with control. In septic rats treated with TNFbp, plasma and skeletal muscle lactate concentrations were significantly decreased compared with untreated septic rats. In skeletal muscle, sepsis resulted in a 70% decrease in the proportion of the PDH in the active form compared with controls. The sepsis-induced inhibition in the PDH complex activity was prevented by TNFbp. PDH kinase was enhanced 1.8-fold in sepsis, and the increase in PDH kinase activity was prevented by treatment with TNFbp. TNFbp treatment did not have any effects on plasma lactate or the proportion of active skeletal muscle PDH activity in control animals.
CONCLUSIONS: TNFbp prevents the sepsis-induced hyperlactatemia and derangements in skeletal muscle lactate concentrations and PDH activity. These observations suggest that TNF is an important mediator responsible for lactate dyshomeostasis during sepsis. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790813     DOI: 10.1006/jsre.1998.5324

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  Pyruvate Dehydrogenase Activity Is Decreased in the Peripheral Blood Mononuclear Cells of Patients with Sepsis. A Prospective Observational Trial.

Authors:  Erin Nuzzo; Katherine M Berg; Lars W Andersen; Julia Balkema; Sophia Montissol; Michael N Cocchi; Xiaowen Liu; Michael W Donnino
Journal:  Ann Am Thorac Soc       Date:  2015-11

2.  The epidemiology of acute respiratory distress syndrome in patients presenting to the emergency department with severe sepsis.

Authors:  Mark E Mikkelsen; Chirag V Shah; Nuala J Meyer; David F Gaieski; Sarah Lyon; Andrea N Miltiades; Munish Goyal; Barry D Fuchs; Scarlett L Bellamy; Jason D Christie
Journal:  Shock       Date:  2013-11       Impact factor: 3.454

3.  Temporal changes in the involvement of pyruvate dehydrogenase complex in muscle lactate accumulation during lipopolysaccharide infusion in rats.

Authors:  N Alamdari; D Constantin-Teodosiu; A J Murton; S M Gardiner; T Bennett; R Layfield; P L Greenhaff
Journal:  J Physiol       Date:  2008-01-24       Impact factor: 5.182

Review 4.  Clinical review: anticoagulation for continuous renal replacement therapy--heparin or citrate?

Authors:  Heleen M Oudemans-van Straaten; John A Kellum; Rinaldo Bellomo
Journal:  Crit Care       Date:  2011-01-24       Impact factor: 9.097

Review 5.  The Pyruvate Dehydrogenase Complex in Sepsis: Metabolic Regulation and Targeted Therapy.

Authors:  Zhenhua Zeng; Qiaobing Huang; Liangfeng Mao; Jie Wu; Sheng An; Zhongqing Chen; Weijin Zhang
Journal:  Front Nutr       Date:  2021-12-14

6.  Exercise-induced AMPK and pyruvate dehydrogenase regulation is maintained during short-term low-grade inflammation.

Authors:  Rasmus Sjørup Biensø; Jesper Olesen; Line van Hauen; Simon Meinertz; Jens Frey Halling; Lasse Gliemann; Peter Plomgaard; Henriette Pilegaard
Journal:  Pflugers Arch       Date:  2014-04-02       Impact factor: 3.657

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.